Latest news with #Ampersand
Yahoo
22-05-2025
- Business
- Yahoo
Ampersand Capital Partners Ranked #1 Globally for Growth Capital Private Equity Performance for the Third Consecutive Year by HEC Paris–Dow Jones
HEC Paris Boston, MA, May 22, 2025 (GLOBE NEWSWIRE) -- Ampersand Capital Partners has ranked #1 for growth capital private equity performance globally by HEC Paris–Dow Jones, marking the third consecutive year the firm has earned this prestigious distinction. 'This achievement reflects the dedication and depth of our investment team, our disciplined focus in the healthcare sector, and the outstanding efforts of our portfolio company management teams,' said Herb Hooper, Managing Partner at Ampersand Capital Partners. 'We are honored to be recognized by such a prestigious institution as HEC Paris-Dow Jones.' The annual ranking, led by Professor Oliver Gottschalg of HEC Paris in collaboration with Dow Jones, analyzed the performance of 278 growth capital firms and 505 funds raised between 2011 and 2020, with an aggregate equity volume of $329B. The report for 2024 notes increased global competition in the growth capital landscape, including the entrance of UK and Japanese firms into the global Top 10 for the first time. Despite this heightened competition, Ampersand maintained its leadership position, underscoring its sustained and consistent performance. Source: The HEC Paris-Dow Jones Growth Capital Performance Ranking of Growth Capital Funds 2024 was issued on May 12, 2025 based on data gathered as of December 2024. HEC Paris analyzed performance data from 278 growth capital firms and the 505 funds they raised between 2011 and 2020 with an aggregate equity volume of $329B. The ranking, conducted by Professor Oliver Gottschalg from HEC Business School in Paris and Dow Jones, evaluated private equity fund performance provided by Preqin and data reported directly to HEC Paris-DowJones. Ampersand did not provide cash or non-cash compensation directly or indirectly in connection with obtaining or using this ranking. Past performance and such ranking are not a guarantee of future results. See the full report and methodology here. About Ampersand Capital Partners Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit or follow us on LinkedIn. Attachment HEC Paris CONTACT: Kathleen Toomey Ampersand Capital Partners kpt@
Yahoo
22-05-2025
- Business
- Yahoo
Ampersand Capital Partners Ranked #1 Globally for Growth Capital Private Equity Performance for the Third Consecutive Year by HEC Paris–Dow Jones
HEC Paris Boston, MA, May 22, 2025 (GLOBE NEWSWIRE) -- Ampersand Capital Partners has ranked #1 for growth capital private equity performance globally by HEC Paris–Dow Jones, marking the third consecutive year the firm has earned this prestigious distinction. 'This achievement reflects the dedication and depth of our investment team, our disciplined focus in the healthcare sector, and the outstanding efforts of our portfolio company management teams,' said Herb Hooper, Managing Partner at Ampersand Capital Partners. 'We are honored to be recognized by such a prestigious institution as HEC Paris-Dow Jones.' The annual ranking, led by Professor Oliver Gottschalg of HEC Paris in collaboration with Dow Jones, analyzed the performance of 278 growth capital firms and 505 funds raised between 2011 and 2020, with an aggregate equity volume of $329B. The report for 2024 notes increased global competition in the growth capital landscape, including the entrance of UK and Japanese firms into the global Top 10 for the first time. Despite this heightened competition, Ampersand maintained its leadership position, underscoring its sustained and consistent performance. Source: The HEC Paris-Dow Jones Growth Capital Performance Ranking of Growth Capital Funds 2024 was issued on May 12, 2025 based on data gathered as of December 2024. HEC Paris analyzed performance data from 278 growth capital firms and the 505 funds they raised between 2011 and 2020 with an aggregate equity volume of $329B. The ranking, conducted by Professor Oliver Gottschalg from HEC Business School in Paris and Dow Jones, evaluated private equity fund performance provided by Preqin and data reported directly to HEC Paris-DowJones. Ampersand did not provide cash or non-cash compensation directly or indirectly in connection with obtaining or using this ranking. Past performance and such ranking are not a guarantee of future results. See the full report and methodology here. About Ampersand Capital Partners Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit or follow us on LinkedIn. Attachment HEC Paris CONTACT: Kathleen Toomey Ampersand Capital Partners kpt@
Associated Press
11-02-2025
- Business
- Associated Press
Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. 'We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to advance programmed biologics that precisely target disease while sparing healthy tissues,' said Jason Gardner, CEO and Director of Ampersand Biomedicines and CEO-Partner at Flagship Pioneering. 'Her deep experience in business development, strategic partnerships, and corporate finance, as well as her leadership in advancing breakthrough therapies, will be invaluable as we continue to grow Ampersand and create best-in-class therapeutics.' Mily currently serves as CEO of the T1D Fund, an impact investing fund focused on advancing therapies and cures for Type 1 Diabetes. Prior to this role, she was the Executive Vice President of Strategy & Business Development at Bristol-Myers Squibb, where she led the company's strategic approach to sourcing external innovation, including mergers and acquisitions, strategic partnerships, alliance management and equity investments. Before joining Bristol-Myers Squibb, Mily held senior leadership positions at Barclays, where she led its Life Sciences investment banking business, as well as at Thermo Fisher Scientific as Senior Vice President, Corporate Strategy and Development. Earlier in her career, she spent 16 years at Goldman, Sachs & Co. as a Managing Director and senior coverage officer in the Healthcare Investment Banking Division. Mily currently serves as a director of Solventum Corporation (NYSE: SOLV), including membership on the Audit and Quality, Science & Technology Committees. 'Ampersand has the potential to transform biologic drug development by programming medicines to be more selective, enhancing both precision and patient outcomes,' said Mily. 'The company has already made remarkable progress, and I look forward to joining the board at this pivotal time and working with the team to advance Ampersand to the next stage of growth.' About Ampersand Biomedicines Ampersand Biomedicines enables a new way of programming medicines that work precisely where needed in the body and nowhere else. The company's computationally powered Address, Navigate, Determine (AND)™ Platform identifies ideal addresses for drug localization and informs the design of AND-Body™ Therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded by Flagship Pioneering in 2021. For more information, please visit and follow us on LinkedIn. Media Contact: Josephine Zorbo, Ph.D.
Yahoo
27-01-2025
- Health
- Yahoo
Trudeau Institute, Ampersand Biosciences producing tools for flu research with $1M grant
SCIENCE: Trudeau Institute, Ampersand Biosciences producing tools for flu research with $1M grant SARANAC LAKE — Local research and biotechnology laboratories Trudeau Institute and Ampersand Biosciences have received a $1 million grant to produce tools aiding the research of the flu. The $1,084,824 grant is a second-phase Small Business Innovative Research grant from the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health. This builds on two previous phase-one SBIR awards the two laboratories received to generate reagents for studying infectious diseases like the flu or coronavirus. Reagents are molecules that make it easier for scientists to test what is happening in test animals' immune systems when they are infected with the flu — and what happens when they get treatment or a vaccine. In this case, the reagents are proteins, specifically, monoclonal antibodies. After the reagents are created and validated, Ampersand sells them to the scientific community to be used in more research. This second phase will be a two-year study digging deeper into testing some of these molecules. FLU DEATHS Deb Brown, principal investigator at Saranac Lake-based Trudeau Institute, said what they produce will be a tool for the whole influenza research community. The flu causes close to 500,000 deaths annually worldwide. It's a common viral disease, known for causing lethargy, difficulty in breathing and high fevers. According to the World Health Organization, there are around 1 billion cases of the flu worldwide annually, with 3 to 5 million causing severe illness. According to the WHO, 99% of flu-related deaths are in children under the age of 5, mostly in developing countries. In the United States, the flu causes around 36,000 deaths each year. Here, 90% of these deaths are in people 65 or older. Brown's influenza lab at Trudeau Institute already studies the disease in mice. Now, they'll use ferrets. Ferrets are better than mice for researching influenza for several reasons. For one, ferrets have lungs which are more similar to human lungs than mice. Also, ferrets have a much stronger sneeze reflex than mice. This allows them to study the spread of the disease and vaccine responses better, because infected ferrets can transmit the flu to each other. REAGENT KITS Dr. Tori Race is the principal investigator at Lake-Clear based Ampersand Biosciences. Ampersand specializes in the development of reagents and sells them in kits. A $596,519 grant in 2020 led to the development of 14 different reagents to detect 'biomarkers' in animals. Biomarkers are molecules in blood and tissue which signal infection. These reagents are currently being sold by Ampersand to support research on diseases like influenza and COVID-19. This is the first time these molecules have been available to the research community. The first phase took a 'tremendous amount of work,' Race said. Part of the second phase is to make these reagent tools available for more researchers. Currently, they are used in a specialized and expensive machines. Now, the laboratories are working to make these tools usable with less expensive and more common machines. Though the tools they're producing can't be used in human studies, the lessons learned can be adapted to apply to human studies. FIGHTING CYTOKINE STORMS Brown said one of the things the researchers will use the reagents for is to see if there's less of an inflammatory response, or cytokine storm, when treated with vaccines or therapeutic drugs. A cytokine storm is an extreme immune response to infection with rapid inflammation. It is a cause of severe and fatal cases of the flu or COVID-19. Essentially, the immune system is overreacting to the infection, which inhibits breathing. 'Researchers are trying to develop therapeutics to combat this, so now we can test for that in these better animal models,' Brown said. Brown's work focuses on making flu vaccines more universal, to protect against many different strains of the illness, instead of just the one that's around in a given year. For all the scientific advancement in vaccines, she said we still don't have good vaccines for the flu. Strategies which worked for diseases like small pox, measles and mumps don't work for influenza because it changes and mutates so rapidly. She is interested in looking at the bodily immune response to the virus, and using that knowledge to develop better vaccines. Part of this new grant is meant to use new methods that can detect both the type of immune cell in the lung, as well as that cell's function. 'Can we design a vaccine that acts more like our own immune response?' Brown asked, 'to provide protection against more than just the viruses that are circulating year-to-year.' REASONS TO CELEBRATE She said it feels great to provide brand-new information and research for the whole immunology community. Not everyone has the ability to do research with ferrets, so others rely on places like Trudeau Institute to provide that research. 'There's an immense sense of pride, honestly,' Race said. 'Whenever a kit is ordered we celebrate.' They have a world map on the wall of their offices and place a push-pin on cities wherever they've sold kits. So far, they've sold more than 70 ferret multiplex kits. 'While it seems modest, these sales mean a lot to our small business of seven people,' Race said. 'Any additional minds we have working on the development of vaccines and therapeutics in this important area, the better.' The National Institutes of Health and Centers for Disease Control and Prevention are some of Ampersand's biggest customers. Brown said it's neat to have a bio-tech hub with Trudeau, Ampersand and Bionique Testing Laboratories all in the Saranac Lake area. Race said they collaborate with Trudeau as often when they can. Undergraduate students from Hamilton College just started helping Brown with her work on mouse influenza models this week.
